Drug intelligence / Profile preview

mercury-197m

Development stage
Preclinical
Lead developer
Helmholtz-Zentrum Dresden-Rossendorf
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

Mercury-197m (Hg-197m) is a cyclotron-produced, theranostic radionuclide with a half-life of approximately 23.8 hours. It decays via electron capture and isomeric transition to mercury-197 (Hg-197), emitting low-energy gamma rays suitable for single-photon emission computed tomography (SPECT) imaging, alongside a cascade of conversion and Auger electrons. These high-LET (linear energy transfer) Auger electrons deposit highly localized, cytotoxic radiation within a short range (nanometer to micrometer scale), making Hg-197m highly effective for targeted radionuclide therapy of micrometastases and small tumors while minimizing damage to surrounding healthy tissue. Preclinical research focuses on chelating Hg-197m with sulfur-rich macrocycles to conjugate it to tumor-targeting vectors such as monoclonal antibodies (e.g., panitumumab, trastuzumab) or nanoparticles for cancer theranostics.

Other names
197mHgHg-197mHg197mHg 197mmercury-197mmercury197mmercury 197mradioactive mercury-197m
02

Identity

Drug type
Radiopharmaceuticals
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Route
IntratumoralIntravenous
04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsPreclinicalActive
glioblastoma, IDH-wildtypePreclinicalActive
prostate cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Helmholtz-Zentrum Dresden-RossendorfLead developer
07

Patents & exclusivity

Patents
3

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
608
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. bleomycin A2Approved
  4. dacomitinibApproved
  5. eribulinApproved

Beyond the preview

Go deeper on mercury-197m.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mercury-197m.

Work on mercury-197m? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call